Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 13, 2017Eisai Announces Perampanel Data in Epilepsy at the 2017 American Academy of Neurology Annual MeetingMeta-analysis on the extrapolation of adult antiepileptic drug efficacy data, including perampanel, to pediatric patients to be featured in "Best Of" oral presentation panel
Eisai Inc. announced today that eight poster presentations featuring data on the safety and efficacy of perampanel (marketed as FYCOMPA® CIII) in a range of seizure types will be presented at the...
-
Mar 28, 2017Research to be presented spans four of the Company's investigational and marketed oncology therapies, both as single agents and in combination
Eisai Inc. announced today 13 presentations of clinical and preclinical research at the American Association for Cancer Research (AACR) 2017 Annual Meeting, April 1 – 5, 2017 in Washington, D.C....
Mar 23, 2017Eisai Inc. is pleased to announce that it will be launching the latest "Medikidz Explain Epilepsy," book as part of their participation at the Epilepsy Foundation's National Walk for Epilepsy on...
Mar 17, 2017Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the immediate appointment of Kirk Shepard, MD, as Senior Vice President, Global Medical Affairs of the Oncology...
-
Jan 25, 2017
Eisai Inc. today announced positive topline results from the randomized, multicenter Phase 3 trial (Study 304) evaluating the company's multiple receptor tyrosine kinase inhibitor, lenvatinib...